title: [Digitalis for the treatment in patients with heart failure].
abstract: Digitalis glycosides are the first-choice drugs in the treatment of the patients with congestive heart failure and atrial fibrillation. Recently, it has been shown that digitalis glycosides have potentially beneficial neurohumoral modulating effects by decreasing excessive neurohumoral responses directly or by improving baroreflex mechanisms in congestive heart failure. Accordingly, there are many investigators who believe that digitalis glycosides are neurohormonal modulating agents in heart failure. There may be a dissociation between hemodynamic and neurohormonal effects in response to digitalis glycosides. The activation of the neurohormonal system may be present in patients with asymptomatic left ventricular dysfunction. Digitalis glycosides may therefore be used, not only to improve symptomatic congestive heart failure, but also to protect against the progressive deterioration of asymptomatic cardiac dysfunction.
authors.affiliation: 2nd Department of Medicine, Teikyo University School of Medicine.
authors.forename: T
authors.initials: T
authors.lastname: Sato
authors.forename: M
authors.initials: M
authors.lastname: Takeshi
authors.forename: M
authors.initials: M
authors.lastname: Ochiai
mesh_terms: D009320:Atrial Natriuretic Factor / Q000097:blood; D004070:Digitalis; D004077:Digoxin / Q000097:blood; D006333:Heart Failure / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D009638:Norepinephrine / Q000097:blood; D010946:Plants, Medicinal; D010947:Plants, Toxic; D012083:Renin / Q000097:blood
chemical_list: D004077:Digoxin; D009320:Atrial Natriuretic Factor; D012083:Renin; D009638:Norepinephrine